Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782210 · ClinicalTrials.gov registry record · Phase 3
12 / 48 Week Pivotal PFT vs PBO in COPD I
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 625
- Enrollment target
NCT00782210 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 625 participants.
The verdict
NCT00782210, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 625 participants
- Enrollment target
Study Summary
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD). The safety of BI 1744 CL inhalation solution delivered through the Respimat inhaler will also be compared to placebo.
Interventions
- DRUG placebo
- DRUG Olodaterol (BI1744)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 625 participants |
| Start Date | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782210
The ClinicalTrials.gov registry entry for NCT00782210 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 625 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00782210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782210 about?
NCT00782210 is a clinical study titled "12 / 48 Week Pivotal PFT vs PBO in COPD I". This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD). The safety of BI 1744 CL inhalation solution delivered through the Respimat inhaler ...
What is the current status of trial NCT00782210?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 625 participants. The study started on 2008-11.
What interventions are being tested in trial NCT00782210?
The interventions under investigation include: placebo (DRUG), Olodaterol (BI1744) (DRUG).
Who is sponsoring clinical trial NCT00782210?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.